GELS: Pangali Forward P/E Gelteq Limited

Gelteq Limited is recognized as an expert in developing convenient oral gels for drug delivery. The company's forward P/E chart helps assess the stock's valuation relative to future earnings, with the metric holding around 0.00. Business development relies on a staff of leading biotechnologists and a strategic search for a global partner to license unique patents.

Gelteq Limited - Rasio rega marang bathi sing dikarepake GELS (periode 30.10.2024 - 14.11.2026)

Gelteq Limited Inc (GELS) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:

Bagan rega Gelteq Limited|GELS - Bagan rega target

- informasi kapitalisasi pasar:

Kapitalisasi pasar Gelteq Ltd|GELS - Rega Tumbas Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham Gelteq|GELS - Nilai Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku gelteq.com|GELS - Aset Perusahaan

- rincian utang lan likuiditas:

- rincian asil keuangan lan kelipatan valuasi:

GELS - Bathi resik|Bathi sing dikarepake Gelteq Limited|GELS - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Gelteq Limited|GELS - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Gelteq Ltd|GELS - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Gelteq|GELS - Bathi resik saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan gelteq.com|GELS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Gelteq Limited

- indikator dodolan lan pendapatan:

GELS - Pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan Gelteq Limited|GELS - Kapitalisasi marang volume dodolan|Multiplikator Forward P/S Gelteq Ltd

Pambiji fundamental:GELS Gelteq

Gelteq Limited is scaling its presence in the pharmaceutical sector through innovative gel-based delivery of active substances, which makes the company's forward P/E ratio an indicator of market expectations for future business profits. This metric compares current market capitalization with projected net income, accounting for the weighted average cost of capital (WACC), allowing investors to promptly recognize the risk of overpaying for the asset during a sharp increase in the coefficient.

Analisis pesaing Gelteq Limited

Rega marang bathi mangsa ngarep Vertex (VRTX)|Rega marang bathi mangsa ngarep ALNY (Alnylam Pharmaceuticals, Inc.)|Pangali Forward P/E INSM (Insmed Inc)|Kapitalisasi marang proyeksi bathi United Therapeutics Inc. (UTHR)|BMRN: Prakiraan rega marang bathi|Rasio rega marang bathi sing dikarepake BBIO|BGM: Pangali Forward P/E|Rasio prakiraan rega marang bathi Cogent Biosciences Inc (COGT)|XERS (Xeris Biopharma Inc) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep KROS (Keros Corp)|Prakiraan rega marang bathi ARCT (Arcturus Therapeutics)|ETON (etonpharma.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Kamada KMDA|FULC (Fulcrum Therapeutics Inc) - Rasio rega marang bathi sing dikarepake|Abeona - Pangali Forward P/E|Pangali mangsa ngarep rega marang bathi MREO (Mereo BioPharma)|PLX: Pangali Forward P/E|Pliant Therapeutics, Inc. (PLRX) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Applied Therapeutics, Inc.|RNTX: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Aytu BioPharma, Inc. (AYTU)|Prakiraan rega marang bathi chemomab.com CMMB|Pangali Forward P/E SRXH (SRx Health Solutions)|Pangali Forward P/E Polyrizon Limited PLRZ|Zentaris - Pangali Forward P/E|Pangali forward rega marang bathi Cyclo Therapeutics Inc. (CYTH)|INZY: Pangali Forward P/E|Rasio prakiraan rega marang bathi Reneo Pharmaceuticals, Inc (RPHM)|Rega marang bathi mangsa ngarep COSCIENS Biopharma Inc.